Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Boryung Pharmaceutical has added Eli Lily's Gemzar among the anti-cancer drugs that it has rights to distribute in South Korea.
Boryung also has distribution rights to such anti-cancer drugs as Oxalitin (oxaliplatin) and Genexol (paclitaxel).
Boryung CEO Ahn Jae-hyun promised to continue growing its anti-cancer portfolio as the company's focal point.
Gemzar (gemcitabine), a nucleoside metabolic inhibitor, is mainly a pancreatic cancer treatment drug.
Combined with other drugs, Gemzar is used for the treatment of metastatic breast cancer, advanced ovarian cancer, and non-small cell lung cancer.
Gemzar posted 14.2 billion won in revenue in South Korea last year.
